Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram.
about
Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expressionIdentification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected]Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safetyDetermination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by 1H NMR and identification of the membrane association domain using chimeric constructsThe human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipramThe unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domainsAssociation with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibitionTAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acidHuman PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary changeAttenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10ARegulation of glypican-1, syndecan-1 and syndecan-4 mRNAs expression by follicle-stimulating hormone, cAMP increase and calcium influx during rat Sertoli cell developmentMembrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulumThe SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5)PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cellsIntracellular membrane association of the Aplysia cAMP phosphodiesterase long and short forms via different targeting mechanisms.Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C).ABCD of the phosphodiesterase family: interaction and differential activity in COPDPDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalizationCharacterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitorsLong PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)Cyclic AMP levels, adenylyl cyclase activity, and their stimulation by serotonin quantified in intact neurons.Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum.Multiple transcripts for the human cardiac form of the cGMP-inhibited cAMP phosphodiesterase.Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.State-dependent disruption of short-term facilitation due to overexpression of the apPDE4 supershort form in AplysiaSuppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase.Distinct phosphodiesterase-4D variants integrate into protein kinase A-based signaling complexes in cardiac and vascular myocytes.Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase geneSubcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene.cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regionsExpression and regulation of human and rat phosphodiesterase type IV isogenes.Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
P2860
Q22254649-1E17720F-3C91-4012-B6C3-FEECB40F6A6DQ24317630-2CCE5CC7-895B-4AB7-AA5D-BEF802C6BE29Q24528252-0F19D1BE-1372-4A0E-AFC1-F05EF61F1153Q24530596-53E1D8C5-7866-4D21-9EDB-EC7ECD5DEDFAQ24533566-5552B46A-9176-4CCB-B538-DEED4F06FC91Q27658795-4D122507-3243-4F8B-BCBD-A0C2B5D45C4DQ27732838-09B45A99-E49C-4A97-9ED6-182EF51CDE0DQ28115926-B1656ACA-4578-43B1-8C3C-9FCA86732593Q28138448-1D4764F8-58E8-4251-8490-7CE4157004F7Q28141780-7D113225-4900-4A3C-A878-3A9D976D83CBQ28216705-53DFAE2F-9140-483F-A074-81348DA792A9Q28261760-F8FB7041-25B4-4F0B-838B-B328E3B1ED31Q28573529-04A3465D-BF57-4EDF-A58E-C67E1073E3BEQ28574633-8367FE72-4186-488E-9143-A19A962B8BB3Q28583904-A87E1FCF-92DF-4897-AA02-BA20D0CD24A0Q28594129-77BD02AD-4F13-4D97-8AEB-BEAA4292FC1DQ30176855-FA147D98-8EE2-41B8-ACC9-DB2022088A9EQ34156231-8820A579-8AEE-4BAD-B55E-FC9686E1DD75Q34170786-13B0FC52-623C-4562-937B-461465C521E7Q34317686-647B6204-2108-4A1A-A3D4-104B39C28EEDQ34961511-66C9CC55-6300-46D5-9D7E-D5688156A4FFQ35005680-2277079B-E559-40E9-9D2A-C9587FF5F954Q35027541-C0537DB5-7D80-4E36-B951-A10ECD5724A8Q35044409-C62110AB-E164-4AD1-B276-F0C682434548Q36435866-BD77ED04-8239-4B01-A071-16BACCAC6703Q36698478-BCEAABFC-4179-4566-ABFB-463A72371099Q36707674-79B07EE1-59AC-4070-AA21-C6190F8B4C10Q36843124-0204286C-EAA5-437A-BD51-D663E2E6716CQ37041337-34491D30-C36B-4186-8F95-A93BCB96A055Q37599416-047FEC65-5760-4A27-8252-45B6B58F91E2Q38296083-2E7E312B-4A0F-4834-A308-5DBAC5FEB54CQ38332843-82CE5FA8-40C5-4A3C-A253-F5632B424046Q39908253-3C84955C-7163-46DA-88AC-DF629FCAC9CAQ40577866-CAD38CE8-61CB-4EC3-97A1-9202BA604219Q41022571-353958C0-DF35-434A-8511-04A886EFFEB0Q41030925-C836E923-6323-4DD9-91A9-331095CA62E3Q41295240-CE4BD6EE-62BE-4ED4-B968-1C186B0C9A24Q41413597-BDE07F6A-9D90-4DFB-B8FD-70CD8CE1741CQ41447861-C4E2AFAC-FEFF-464F-9E1F-4D9075BFAF53Q41708863-B744234D-ADFB-4E86-BA2F-DD16E339B3D6
P2860
Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Engineered deletion of the uni ...... ity to inhibition by rolipram.
@en
type
label
Engineered deletion of the uni ...... ity to inhibition by rolipram.
@en
prefLabel
Engineered deletion of the uni ...... ity to inhibition by rolipram.
@en
P2860
P356
P1433
P1476
Engineered deletion of the uni ...... ity to inhibition by rolipram.
@en
P2093
P2860
P304
P356
10.1042/BJ2920677
P407
P478
292 ( Pt 3)
P577
1993-06-01T00:00:00Z